Type 2 diabetes or prediabetes: GLP-1 medications help regulate blood sugar and improve insulin response
GLP-1: What Each Receptor Contributes GLP-1 receptor activation slows gastric emptying, suppresses glucagon, and drives satiety signals through vagal afferents
Results from our models are reported as odds ratios (Binomial), incidence rate ratios (Poisson) with 95% confidence intervals, and parameter estimates (Gaussian) with standard error of the means
Clinical evidence, encompassing trials, epidemiological investigations, and findings from animal toxicology and histological studies, has revealed potential associations between GLP-1RAs and the risk of neuroendocrine tumors and exocrine pancreatic dysplasia, with some evidence suggesting an increased risk of pancreatic cancer [6]
Results from Eli Lilly's Phase III study for the GLP-1 are being presented at the ADA's 85th Scientific Sessions in June and additionally published in a journal
Y.ZhuY.XieQ